CAS 2055362-74-6

(Z)-4-[5-(3-Benzyl-2,4-dioxo-thiazolidin-5-ylidenemethyl)-furan-2-yl]-benzoic acid (2-Hydroxy-ethyl)-trimethyl-ammonium

CAS : 2055362-74-6

Formule : C₂₇H₂₉N₂O₅S₂

Degré de pureté : 95%

Couleur et forme : Solid

Masse moléculaire : 525.6596

Ref: IN-DA01JQC9

ADH-503

CAS : 2055362-74-6

ADH-503

Degré de pureté : ≥95%

Masse moléculaire : 524.7g/mol

Ref: 54-BUP13161

ADH-503

CAS : 2055362-74-6

ADH-503 (GB1275) is an orally available, allosteric CD11b small molecule agonist.Cost-effective and quality-assured.

Formule : C₂₇H₂₈N₂O₅S₂

Degré de pureté : 97.03% - >99.99%

Couleur et forme : Solid

Masse moléculaire : 524.7

Ref: TM-T7776

2-Hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate

CAS : 2055362-74-6

Formule : C₂₇H₂₈N₂O₅S₂

Degré de pureté : ≥98%

Masse moléculaire : 524.65

Ref: 10-F546535

ADH-503

CAS : 2055362-74-6

ADH-503 is a small-molecule drug that is used as an anti-cancer agent. It inhibits tumor growth by targeting the mitochondria and microenvironment. ADH-503 has been shown to inhibit tumor cells in vitro and in vivo through various mechanisms, such as inhibiting the production of growth factors, reducing reactive oxygen species (ROS) levels, and inhibiting angiogenesis. In addition, ADH-503 has been shown to be effective against chronic viral infections and cancer cells with mitochondrial DNA mutations. Clinical studies have demonstrated that ADH-503 can reduce the incidence of myeloid-derived suppressor cells (MDSCs) in patients with acute myeloid leukemia (AML).

Formule : C₂₂H₁₄NO₄S₂·C₅H₁₄NO

Degré de pureté : Min. 95%

Masse moléculaire : 524.65 g/mol

Ref: 3D-FHD36274